806 related articles for article (PubMed ID: 7564517)
1. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
3. IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Jan; 9(1):216-22. PubMed ID: 7845021
[TBL] [Abstract][Full Text] [Related]
4. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
5. Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.
Marshall GM; Kwan E; Haber M; Brisco MJ; Sykes PJ; Morley AA; Toogood I; Waters K; Tauro G; Ekert H
Leukemia; 1995 Nov; 9(11):1847-50. PubMed ID: 7475273
[TBL] [Abstract][Full Text] [Related]
6. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
[TBL] [Abstract][Full Text] [Related]
7. [Children with acute lymphoblastic leukemia: prognostic significance of polymerase-chain-reaction analysis of minimal residual disease].
Steenbergen EJ; Verhagen OJ; van den Berg H; van Leeuwen EF; von dem Borne AE; van der Schoot CE
Ned Tijdschr Geneeskd; 1996 Jan; 140(1):22-8. PubMed ID: 8569906
[TBL] [Abstract][Full Text] [Related]
8. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
9. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
11. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse.
Biondi A; Yokota S; Hansen-Hagge TE; Rossi V; Giudici G; Maglia O; Basso G; Tell C; Masera G; Bartram CR
Leukemia; 1992 Apr; 6(4):282-8. PubMed ID: 1316978
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
Miglino M; Berisso G; Grasso R; Canepa L; Clavio M; Pierri I; Pietrasanta D; Gatto S; Varaldo R; Ballerini F; Verdiani S; Casarino L; DeStefano F; Sessarego M; Dominietto A; Raiola AM; Bregante S; di Grazia C; Gobbi M; Bacigalupo A
Bone Marrow Transplant; 2002 Nov; 30(9):579-85. PubMed ID: 12407432
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
19. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
[TBL] [Abstract][Full Text] [Related]
20. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
